Cancer and chronic inflammation are partners in peril, with the latter increasing the likelihood that malignant tumors will develop, grow and spread. Researchers at the University of California, San Diego School of Medicine say they've identified a tumor inflammation trigger that is common to most, if not all, cancers. And using existing inhibitory drugs, the scientists were able to dramatically decrease primary tumor growth in animal studies and, more importantly, halt tumor progression and metastasis.
The findings appear in the June 14 issue of the journal Cancer Cell, authored by Judith A. Varner, PhD, professor of medicine at the UC San Diego Moores Cancer Center, and colleagues in the UCSD School of Medicine and at the University of Torino, Italy.
When cancer cells appear in the body, they often provoke an immune system response. Under some circumstances, this is a good thing. But Varner and colleagues were able to show that when responding myeloid or white blood cells called macrophages are drawn to invasive cancer cells, the result can be considerable trouble for patients. Rather than suppressing the cancer, the myeloid cells are tricked by the tumor into aiding and abetting its growth and spread. Scientists have long recognized that myeloid cells can invade and promote tumor growth. But until now it was not fully appreciated how this hijacking occurs and whether there are ways to disrupt this process by suppressing the trigger that leads to myeloid cell recruitment into tumors.
Probing more deeply into the tumor inflammation process, the UCSD research team identified a range of tumor-produced molecules that attract these dangerous myeloid cells. They also pinpointed the specific trigger on myeloid cells enabling them to invade the tumor environment and accelerate tumor growth and metastasis. It is an enzyme called PI-3 kinase gamma on myeloid cells that turns on an adhesion receptor allowing the cells to enter tumors.
When researchers blocked the activity of PI-3-kinase-gamma, either genetically or through the use of a drug designed for this purpose, myeloid cells were blocked access into tumors, resulting in reduced tumor growth and a dramatic decrease in metastasis. Without the recruitment of myeloid cells, Varner said, the capability of a cancer tumor to grow is largely stifled.
"Most strategies targeting the role of myeloid cells in cancer have focused on reducing their expression of inflammatory molecules," Varner explained. "We've found a single convergent point - the PI-3 kinase-gamma enzyme - that, when blocked, appears to result in significant suppression of tumor inflammation and growth regardless of the initiating event. It could be a very important therapeutic target for future cancer treatments and could impact most, if not all, types of solid cancer."
Michael Karin, PhD, distinguished professor of pharmacology in UCSD's Laboratory of Gene Regulation and Signal Transduction and a pioneer in inflammation research, agreed: "I think that the inhibition of PI-3K activity represents a very interesting and promising approach for inhibition of tumor-associated inflammation. It seems to fully normalize the tumor microenvironment and provide a new addition to our armamentum of anti-cancer drugs."
Varner said a number of biotechnology companies are pursuing potential drugs using PI-3-kinase inhibitors to treat diseases from cancer to heart disease to arthritis. The PI-3-kinase-gamma protein may be a particularly promising therapeutic target, because it is not widely expressed in the body, and its inhibition would likely produce fewer side effects than many therapeutics.
Co-authors of the research are Michael C. Schmid, Christie J. Avraamides, Philippe Foubert, Joan R.E. Manglicmot, Xiaodan Song and Wolfgang Wrasidlo of the UCSD Moores Cancer Center; Holly C. Dippold and Mark H. Ginsberg, UCSD Department of Medicine; Irene Franco and Emilio Hirsch, Department of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, School of Medicine, University of Torino, Italy; Lesley G. Ellies, UCSD Department of Pathology; Sara L. Blair, UCSD Department of Surgery; and Lissette M. Acevedo and David A. Cheresh, UCSD Moores Cancer Center and UCSD Department of Pathology.
Funding for this research came, in part, from grants from the National Institutes of Health and the California Tobacco Related Disease Research Program.